Matthew D. Galsky

ScholarGPS® ID: 63348704841919

Affiliation

Icahn School of Medicine at Mount Sinai, New York, United States

Affiliation History

Field

Medicine

Discipline

Hematology

Top Specialties

Metrics Summary

Publication Count

693

Predicted Citations

22,371

Predicted h-index

Ranking

Publications and Citation History

Publications based on Top Specialties

Types of Publication

Publications
Books
Patents
NIH/NSF

Add Delete
Urine scRNAseq reveals new insights into the bladder tumor immune microenvironment (journal article) Tran, Michelle A. \| Youssef, Dina \| Shroff, Sanjana \| Chowhan, Disha \| Beaumont, Kristin G. \| Sebra, Robert \| Mehrazin, Reza \| Wiklund, Peter \| Lin, Jenny J. \| Horowitz, Amir \| ... \| Bhardwaj, Nina Journal of Experimental Medicine, volume 221, issue 8 (2024). 10.1084/jem.20240045 Cite \| Source
A first-in-human phase 1a dose-escalation study of BGB-15025 (HPK1 inhibitor) as monotherapy and in combination with tislelizumab (TIS; anti-PD-1 antibody) in patients (pts) with advanced solid tumors. (journal article) Deva, Sanjeev \| Zhou, Caicun \| Bishnoi, Sarwan K. \| Lau, Peter Kar Han \| Tran, Ben \| Ba, Yi \| Galsky, Matt D. \| Wang, Yongsheng \| Zhang, Yanqiao \| Luo, Suxia \| ... \| Yap, Timothy A. Journal of Clinical Oncology, volume 42, issue 16_suppl, pages 2585-2585 (2024). 10.1200/JCO.2024.42.16_suppl.2585 Cite \| Source
Characterization of complete responders to nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node–only metastatic urothelial carcinoma from the CheckMate 901 trial. (journal article) Galsky, Matt D. \| Sonpavde, Guru P. \| Powles, Thomas \| Claps, Melanie \| Burotto, Mauricio \| Schenker, Michael \| Sade, Juan Pablo \| Bamias, Aristotelis \| Beuzeboc, Philippe \| Bedke, Jens \| ... \| Van Der Heijden, Michiel Simon Journal of Clinical Oncology, volume 42, issue 16_suppl, pages 4509-4509 (2024). 10.1200/JCO.2024.42.16_suppl.4509 Cite \| Source
Heterogeneity in methods for estimating renal function in anticancer drug development. (journal article) Karol, Alexander B. \| Fujiwara, Yu \| Paredes, Rodrigo \| Argulian, Anna \| Joshi, Himanshu \| Galsky, Matt D. Journal of Clinical Oncology, volume 42, issue 16_suppl, pages e23002-e23002 (2024). 10.1200/JCO.2024.42.16_suppl.e23002 Cite \| Source
Black patient representation in anti-cancer drug development. (journal article) Karol, Alexander B. \| Paredes, Rodrigo \| Fujiwara, Yu \| Argulian, Anna \| Joshi, Himanshu \| Galsky, Matt D. Journal of Clinical Oncology, volume 42, issue 16_suppl, pages e13680-e13680 (2024). 10.1200/JCO.2024.42.16_suppl.e13680 Cite \| Source
CREST: phase III study of sasanlimab and Bacillus Calmette-Guérin for patients with Bacillus Calmette-Guérin-naïve high-risk non-muscle-invasive bladder cancer (journal article) Steinberg, Gary D \| Shore, Neal D \| Redorta, Joan Palou \| Galsky, Matthew D \| Bedke, Jens \| Ku, Ja Hyeon \| Kretkowski, Michal \| Hu, Hailong \| Penkov, Konstantin \| Vermette, Jennifer J \| ... \| Powles, Thomas B Future Oncology, volume 20, issue 14, pages 891-901 (2024). 10.2217/fon-2023-0271 Cited by (2) \| Cite \| Source
C-reactive protein (CRP) as a prognostic biomarker in patients with urothelial carcinoma: A systematic review and meta-analysis (journal article) Fujiwara, Yu \| Karol, Alexander B. \| Joshi, Himanshu \| Reford, Emma \| Izadmehr, Sudeh \| Doroshow, Deborah B. \| Galsky, Matthew D. Critical Reviews in Oncology/Hematology, volume 197 (2024). 10.1016/j.critrevonc.2024.104352 Cite \| Source
Understanding Adjuvant Therapy for Upper Tract Urothelial Carcinoma (journal article) Berg, Stephanie A. \| Galsky, Matthew D. Journal of Clinical Oncology, volume 42, issue 13, pages 1459-1461 (2024). 10.1200/JCO.23.02679 Cite \| Source
Phase 2 trial of tremelimumab in patients with metastatic urothelial cancer previously treated with programmed death 1/programmed death ligand 1 blockade (journal article) Miller, Eric J. \| Rose, Tracy L. \| Maughan, Benjamin L. \| Milowsky, Matthew I. \| Bilen, Mehmet A. \| Carthon, Bradley C. \| Gao, Xin \| Rapisuwon, Suthee \| Zhao, Qianqian \| Yu, Menggang \| ... \| Galsky, Matthew D. Cancer, volume 130, issue 9, pages 1642-1649 (2024). 10.1002/cncr.35179 Cite \| Source
Novel bladder-sparing approaches in patients with muscle-invasive bladder cancer (journal article) Ben-David, Reuben \| Galsky, Matthew D. \| Sfakianos, John P. Trends in Molecular Medicine (2024). 10.1016/j.molmed.2024.04.004 Cite \| Source
A Case of Hand-Foot Skin Reaction-like Eruption Associated with Pembrolizumab (journal article) Young, Jade \| Eversman, Anna \| Poplausky, Dina \| Suemitsu, Yamato \| Niedt, George \| Galsky, Matthew \| Sparano, Joseph \| Gulati, Nicholas SKIN The Journal of Cutaneous Medicine, volume 8, issue 2, pages 1464-1467 (2024). 10.25251/skin.8.2.21 Cite \| Source
Phase 3 study of disitamab vedotin with pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma that expresses HER2 (DV-001; trial in progress) (journal article) Powles, T. \| Grande, E. \| Van Der Heijden, M. \| Necchi, A. \| Iyer, G. \| Drakaki, A. \| Loriot, Y. \| Sokolowski, K. \| Zhang, W. \| Galsky, M. European Urology, volume 85 (2024). 10.1016/S0302-2838(24)01317-4 Cite \| Source
UTILITY OF CIRCULATING TUMOR DNA STATUS IN PATIENTS WITH DIFFERENT STAGES OF TESTICULAR CANCER (journal article) Ben-David, Reuben \| Tillu, Neeraja \| Tsao, Che-Kai \| Galsky, Matthew \| Atallah, Kyrollis \| Waingankar, Nikhil \| Wiklund, Peter \| Sfakianos, John P. Urologic Oncology: Seminars and Original Investigations, volume 42 (2024). 10.1016/j.urolonc.2024.01.294 Cite \| Source
Tumor characteristics associated with detectable circulating tumor DNA preoperatively in patients with renal masses suspicious for RCC. (journal article) Ben-David, Reuben \| Alerasool, Parissa \| Kalola, Hitasha \| Tillu, Neeraja \| Tsao, Kai \| Galsky, Matt D. \| Attalla, Kyrollis \| Sfakianos, John P. \| Wiklund, Peter \| Waingankar, Nikhil \| Mehrazin, Reza Journal of Clinical Oncology, volume 42, issue 4_suppl, pages 461-461 (2024). 10.1200/JCO.2024.42.4_suppl.461 Cite \| Source
Final study analysis of PRINT: Prostate cancer intensive, non–cross-reactive therapy for CRPC. (journal article) Liaw, Bobby Chi-Hung \| Joshi, Himanshu \| Sheng, Tianxiang \| Tsao, Che-Kai \| Galsky, Matt D. \| Bakst, Richard Lorne \| Stewart, Robert \| Stock, Richard \| Oh, William K. Journal of Clinical Oncology, volume 42, issue 4_suppl, pages 147-147 (2024). 10.1200/JCO.2024.42.4_suppl.147 Cite \| Source
Oral APL-1202 in combination with tislelizumab as neoadjuvant therapy in patients with muscle-invasive bladder cancer (MIBC): Interim analysis of ANTICIPATE phase II trial. (journal article) Galsky, Matt D. \| Sfakianos, John P. \| Ye, Dingwei \| He, Dalin \| Hu, Hailong \| Song, Xiaodong \| Jiang, Haowen \| Li, Hanzhong \| Jiang, Shusuan \| Wang, Bin \| ... \| Zhang, Mingming Journal of Clinical Oncology, volume 42, issue 4_suppl, pages 632-632 (2024). 10.1200/JCO.2024.42.4_suppl.632 Cite \| Source
Performance of a tumor-informed molecular residual disease (MRD) assay in resected bladder cancer with mixed or pure variant histology: Analysis of a real-world multicenter cohort. (journal article) Kommalapati, Ajitha \| Laliotis, George \| Rich, Jordan \| Cumarasamy, Shivaram \| Rivero, Samuel \| Sharma, Shruti \| Palsuledesai, Charuta C \| Malhotra, Meenakshi \| Galsky, Matt D. \| ElNaggar, Adam \| ... \| Basu, Arnab Journal of Clinical Oncology, volume 42, issue 4_suppl, pages 649-649 (2024). 10.1200/JCO.2024.42.4_suppl.649 Cite \| Source
MAIN-CAV: Phase III randomized trial of maintenance cabozantinib (CABO) and avelumab (Av) vs Av after first-line platinum-based chemotherapy in patients (pts) with metastatic urothelial cancer (mUC; Alliance A032001). (journal article) Gupta, Shilpa \| Ballman, Karla V. \| Apolo, Andrea B. \| Sridhar, Srikala S. \| Chen, Ronald C. \| Wen, Yujia \| Yen, Aihua Edward \| Grivas, Petros \| Tan, Alan \| Baghaie, Shiva \| ... \| Rosenberg, Jonathan E. Journal of Clinical Oncology, volume 42, issue 4_suppl, pages TPS714-TPS714 (2024). 10.1200/JCO.2024.42.4_suppl.TPS714 Cited by (1) \| Cite \| Source
Phase 3 open-label, randomized, controlled study of disitamab vedotin with pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma that expresses HER2 (DV-001). (journal article) Galsky, Matt D. \| Grande, Enrique \| Necchi, Andrea \| Koontz, Michael Zach \| Iyer, Gopa \| Campbell, Matthew T \| Drakaki, Alexandra \| Loriot, Yohann \| Sokolowski, Kevin M. \| Zhang, Wei \| Powles, Thomas Journal of Clinical Oncology, volume 42, issue 4_suppl, pages TPS717-TPS717 (2024). 10.1200/JCO.2024.42.4_suppl.TPS717 Cite \| Source
A phase 1, first-in-human, dose-escalation and expansion study of FX-909 in patients with advanced solid malignancies, including advanced urothelial carcinoma. (journal article) Iyer, Gopa \| Gao, Xin \| Rasco, Drew W. \| Milowsky, Matthew I. \| Garmezy, Benjamin \| Rodriguez Rivera, Ildefonso I \| Tepper, Jennifer \| Moles, Melissa Ann \| Gjini, Evisa \| Bowden, Michaela \| ... \| Galsky, Matt D. Journal of Clinical Oncology, volume 42, issue 4_suppl, pages TPS709-TPS709 (2024). 10.1200/JCO.2024.42.4_suppl.TPS709 Cite \| Source

Title	Investigators	Year	Cost	Agency
Dissecting myeloid cell-mediated resistance to immune checkpoint blockade in bladder cancer	Bhardwaj, Nina \| Galsky, Matthew \| ZHU, JUN	2020	$703,400	NATIONAL CANCER INSTITUTE
Clinical Protocol and Data Management	Galsky, Matthew	2020	$280,419	NATIONAL CANCER INSTITUTE
Novel Approach to Facilitate Decisions in Patients w/ Muscle Invasive Bladder CA	Galsky, Matthew \| Diefenbach, MICHAEL A (contact)	2016	$197,300	NATIONAL CANCER INSTITUTE
Novel Approach to Facilitate Decisions in Patients w/ Muscle Invasive Bladder CA	Galsky, Matthew \| Diefenbach, MICHAEL A (contact)	2015	$252,477	NATIONAL CANCER INSTITUTE